Xenetic Biosciences, Inc. (XBIO) — 8-K Filings

8-K Filings (16)

• Xenetic Biosciences Files 8-K Report — Dec 11, 2025 Risk: low
  On December 11, 2025, Xenetic Biosciences, Inc. filed an 8-K report. The filing primarily serves as a notification of events and includes financial statements a
• 8-K Filing — Nov 13, 2025
• Xenetic Biosciences Files 8-K: Material Agreement & Other Events — Oct 14, 2025 Risk: medium
  On October 10, 2025, Xenetic Biosciences, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statemen
• Xenetic Biosciences Files 8-K on Financials — Aug 13, 2025 Risk: low
  Xenetic Biosciences, Inc. filed an 8-K on August 13, 2025, reporting on its results of operations and financial condition, as well as presenting financial state
• Xenetic Biosciences Files 8-K — May 14, 2025 Risk: low
  On May 14, 2025, Xenetic Biosciences, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 945 Concord Street
• Xenetic Biosciences Appoints New Auditor — Apr 10, 2025 Risk: low
  On April 8, 2025, Xenetic Biosciences, Inc. filed an 8-K report to disclose changes in its certifying accountant. The company has appointed Marcum LLP as its ne
• Xenetic Biosciences Files 8-K on Security Holder Vote — Dec 13, 2024 Risk: low
  On December 11, 2024, Xenetic Biosciences, Inc. filed an 8-K report detailing a submission of matters to a vote of its security holders. The filing does not spe
• Xenetic Biosciences Files 8-K on Financials — Nov 13, 2024 Risk: low
  On November 13, 2024, Xenetic Biosciences, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition,
• Xenetic Biosciences Enters Material Definitive Agreement — Nov 7, 2024 Risk: medium
  On November 1, 2024, Xenetic Biosciences, Inc. entered into a material definitive agreement. The company, formerly known as General Sales & Leasing, Inc. and GE
• Xenetic Biosciences Announces Leadership and Compensation Changes — Oct 31, 2024 Risk: medium
  On October 29, 2024, Xenetic Biosciences, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates
• Xenetic Biosciences Files 8-K on Financials — Aug 14, 2024 Risk: low
  On August 14, 2024, Xenetic Biosciences, Inc. filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations, al
• Xenetic Biosciences Appoints New Directors, Adjusts Executive Pay — Jun 21, 2024 Risk: medium
  On June 18, 2024, Xenetic Biosciences, Inc. announced changes in its board of directors and executive compensation. The company elected two new directors, Dr. J
• Xenetic Biosciences Appoints New CMO & CSO, CMO Departs — May 22, 2024 Risk: medium
  On May 16, 2024, Xenetic Biosciences, Inc. announced the appointment of Dr. Jeffrey M. Hackman as Chief Medical Officer and Dr. David M. Goldenberg as Chief Sci
• Xenetic Biosciences Files 8-K on Financials — May 10, 2024 Risk: medium
  On May 10, 2024, Xenetic Biosciences, Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes financial statem
• Xenetic Biosciences Files 8-K on Financials — Mar 22, 2024 Risk: low
  On March 22, 2024, Xenetic Biosciences, Inc. filed an 8-K report detailing its financial results and operations. The company, formerly known as General Sales &
• Xenetic Biosciences (XBIO) Announces Private Placement of Stock & Warrants — Feb 12, 2024 Risk: medium
  Xenetic Biosciences, Inc. (XBIO) filed an 8-K on February 12, 2024, disclosing a private placement of common stock and warrants. This filing indicates the compa

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX